Feb 28 Endo International Plc reported
a 15.6 percent rise in quarterly revenue on Tuesday, largely
driven by demand for its newly launched generic drugs,
quetiapine and ezetimibe.
The Dublin, Ireland-based drugmaker's net loss attributable
to shareholders widened to $3.34 billion, or $14.98 per share,
in the fourth quarter ended Dec. 31, from $118.46 million, or 53
cents per share, a year earlier.
The company took a $3.5 billion asset impairment charge in
the latest quarter, related to its generics reporting unit.
Total revenue rose to $1.24 billion from $1.07 billion.
Quetiapine is an anti-psychotic drug and ezetimibe is used
to treat cholesterol.
(Reporting by Natalie Grover in Bengaluru; Editing by Martina